

Draft agenda
51st meeting of the Biocidal Products Committee (BPC)
27-31 May 2024
Meeting is held as hybrid
Meeting room Urho in ECHA/WebEx

Starts on 27 May at 10:00,
ends on 31 May at 13:00
The time is indicated in Helsinki time.

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-51-2024
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-50

BPC-M-50-2024
For agreement

5. – Administrative issues

5.1. Administrative issues

For information

6. – Work programme for BPC

**6.1. BPC Work Programmes for active substance approval, Union
authorisation, ED assessment and outlook for BPC**

BPC-51-2024-6.1 A, B, C, D
For information

6.2. Update on active substance approval

BPC-51-2024-6.2
For information

6.3. Update on Union Authorisation processes

BPC-51-2024-6.3 A, B, C

For information

6.4. Update on article 75(1)(g) mandates

For information

6.5. Harmonisation of approach on active substance renewal

BPC-51-2024-6.5

For discussion

7. – Applications for approval of active substances*

7.1. Draft BPC opinion on the approval of Medetomidine for PT 21

Previous discussion: WG-I-2024

BPC-51-2024-7.1 A-D

For adoption

7.2. Draft BPC opinion on the approval of Dinotefuran for PT 18

Previous discussion: WG-I-2024

BPC-51-2024-7.2 A-G

For adoption

**7.3. Draft BPC opinion on the approval of Polymeric betaine for PT 8
(closed session)**

Previous discussion: WG-I-2024

BPC-51-2024-7.3 A-D

For adoption

7.4. Draft BPC opinion on the approval of 5-Chloro-2-methyl-2H-isothiazol-3-one (CIT) for PT 6

Previous discussion: WG-I-2024

BPC-51-2024-7.4 A-E

For adoption

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

8. – Union authorisation**

8.1. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Hydrogen peroxide for PT 4

Previous discussion: WG-I-2024

BPC-51-2024-8.1 A, C, D, D1,E
For adoption

8.2. Draft BPC opinion on the Union Authorisation of a biocidal product containing Propan-2-ol for PT2

Previous discussion: WG-I-2024

BPC-51-2024-8.2 A-E
For adoption

8.3. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Propan-1-ol;Propan-2-ol for PT 1

Previous discussion: WG-I-2024

BPC-51-2024-8.3 A-E
For adoption

8.4. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Margosa extract from cold-pressed oil of the kernels of Azadirachta Indica extracted with super-critical carbon dioxide for PT 19

Previous discussion: WG-I-2024

BPC-51-2024-8.4 A-E
For adoption

8.5. Draft BPC opinion on the Union Authorisation of a biocidal product containing Glutaral (Glutaraldehyde); Reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1) for PT 6, 11 and 12

Previous discussion: WG-I-2024

BPC-51-2024-8.5 A-D, D1, E, F
For adoption

8.6. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1) for PT 4, 11 and 12 (closed session)

Previous discussion: WG-I-2024

BPC-51-2024-8.6 A-F
For adoption

** For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by E).

8.7. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Peracetic acid for PT 2, 3 and 4

Previous discussion: WG-I-2024

BPC-51-2024-8.7 A-E

For adoption

8.8. Evaluation of post-authorisation data submitted for a biocidal product family containing Propan-2-ol for PT 2 & 4 (closed session)

Previous discussion: BPC-42

BPC-51-2024-8.8 A, C, E

For adoption

9. – Article 75(1)(g) opinion requests

9.1. Draft BPC opinion on examination of efficacy tier 2 data for RP 1:1 and RP 3:2, PT6 and 13 (4 opinions)

Previous discussions: BPC-43 & EFF WG-I-2024

BPC-51-2024-9.1 A1-4, B1-2, C

For adoption

9.2. Draft BPC opinion on Questions on the risks of exposure of workers to corrosive particles during the use of biocidal products by coarse spraying (Questions 1-3)

Previous discussion: TOX WG-I-2024

BPC-51-2024-9.2 A-I

For adoption

10. – Article 15(2) opinion requests

10.1. Draft BPC opinion on the review of approval of the active substance zineb

Previous discussion: ENV & TOX WG-I-2024

BPC-51-2024-10.1 A-E

For adoption

11. - Any other business

11.1. Clarification about assessment of biocidal products concerning misuse

BPC-51-2024-11.1

For information

12. – Action points and conclusions

**Provisional time schedule for the
51st meeting of the Biocidal Products Committee (BPC)
Hybrid meeting in Helsinki and in WebEx**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following days for BPC opinions.

Monday 27 May: (starts at 10:00 EET/09:00 CET, ends at 17:30 EET/16:30 CET)

Items 1-5	Opening items and administrative issues
Item 6.1	BPC Work Programmes for active substance approval, Union authorisation, ED assessment and outlook for BPC
Item 6.3	Update on Union Authorisation processes
Item 6.4	Update on article 75(1)(g) mandates
Item 7.4	Draft BPC opinion on the approval of 5-Chloro-2-methyl-2H-isothiazol-3-one (CIT) for PT 6

Tuesday 28 May: (starts at 09:30 EET/08:30 CET, ends at 17:30 EET/16:30 CET)

Item 6.2	Update on active substance approval
Item 6.5	Harmonisation of approach on active substance renewal
Item 7.1	Draft BPC opinion on the approval of Medetomidine for PT 21
Item 7.2	Draft BPC opinion on the approval of Dinotefuran for PT 18

Wednesday 29 May: (starts at 10:00 EET/08:30 CET, ends at 17:30 EET/16:30 CET)

Item 7.3	Draft BPC opinion on the approval of Polymeric betaine for PT 8 (closed session)
Item 9.1	Draft BPC opinion on examination of efficacy tier 2 data for RP 1:1 and RP 3:2, PT6 and 13 (4 opinions)
Item 9.2	Draft BPC opinion on Questions on the risks of exposure of workers to corrosive particles during the use of biocidal products by coarse spraying (Questions 1-3)
Item 10.1	Draft BPC opinion on the review of approval of the active substance zineb
Item 8.1	Draft BPC opinion on the Union Authorisation of a biocidal product family containing Hydrogen peroxide for PT 4

BPC-51 official dinner

Thursday 30 May: (starts at 10:00 EET/09:00 CET, ends at 17:30 EET/16:30 CET)

- Item 8.2 Draft BPC opinion on the Union Authorisation of a biocidal product containing Propan-2-ol for PT2
- Item 8.3 Draft BPC opinion on the Union Authorisation of a biocidal product family containing Propan-1-ol;Propan-2-ol for PT 1
- Item 8.4 Draft BPC opinion on the Union Authorisation of a biocidal product family containing Margosa extract from cold-pressed oil of the kernels of Azadirachta Indica extracted with super-critical carbon dioxide for PT 19
- Item 8.5 Draft BPC opinion on the Union Authorisation of a biocidal product containing Glutaral (Glutaraldehyde); Reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1)for PT 6, 11 and 12
- Item 8.6 Draft BPC opinion on the Union Authorisation of a biocidal product family containing Reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1) for PT 4, 11 and 12 (closed session)

Friday 31 May: (starts at 09:30 EET/08:30 CET, ends at 13:00 EET/12:00 CET)

- Item 8.7 Draft BPC opinion on the Union Authorisation of a biocidal product family containing Peracetic acid for PT 2, 3 and 4
- Item 8.8 Evaluation of post-authorisation data submitted for a biocidal product family containing Propan-2-ol for PT 2 & 4 (closed session)
- Item 11.1 Clarification about assessment of biocidal products concerning misuse
- Item 12 Action points and conclusions

End of meeting

oOo